Author: Fiona Craig

Sunda Energy Plc (LSE:SNDA) has announced a rescheduling of the Chuditch-2 appraisal well, now targeting drilling in the first half of 2026. The delay stems from logistical service constraints in Timor-Leste, which have disrupted the original project timeline.

As a result, the farm-in agreement with state-owned energy firm TIMOR GAP has been terminated, although Sunda has indicated that discussions may resume to renegotiate terms. In the meantime, the company is actively seeking alternative funding options and anticipates improved rig availability in the coming year due to shifting market dynamics.

Environmental permitting for the project continues, with final approval expected in the third quarter of 2025. While the revised schedule represents a setback, Sunda maintains its long-term commitment to the Chuditch gas field and is focused on maximizing its value for stakeholders.

About Sunda Energy

Sunda Energy Plc is an AIM-listed exploration and appraisal company focused on natural gas assets in Southeast Asia. Operating through its subsidiary, SundaGas Banda Unipessoal, Lda., the company is primarily engaged in the development of the Chuditch gas project located offshore Timor-Leste.

Caspian Sunrise (LSE:CASP) has shared an update on its ongoing corporate activities, with a focus on the planned $88 million sale of shallow assets within the BNG Contract Area—specifically the MJF and South Yelemes structures. While this divestment is still awaiting regulatory approval, its completion is expected to significantly strengthen the company’s balance sheet and reshape its operational outlook.

However, the delay in receiving the necessary consents may impact the timing of Caspian Sunrise’s 2024 financial report. If the financials cannot be published in time, the company may face a temporary suspension of its share trading on the market.

Separately, the company continues to advance the acquisition of Procyon Investments Limited, which holds exploration rights for the Block 8 structure. Progress on this front has been slow, though recent developments have enabled operational activities to resume at the nearby Sholkara structure.

About Caspian Sunrise

Caspian Sunrise PLC is an oil and gas exploration and production company with a primary focus on assets in Kazakhstan. The company manages several key projects across the region and is involved in both shallow and deep drilling operations as part of its broader energy portfolio.

Thor Energy Plc (LSE:THR), through its wholly owned subsidiary Go Exploration Pty Ltd, has secured three Gas Storage Exploration Licences from the South Australian Government. These licences, situated near Adelaide, mark a significant step forward in the company’s strategy to develop underground gas storage infrastructure and strengthen its foothold in Australia’s evolving energy landscape.

The acquisition of these exploration rights supports Thor’s broader commitment to energy resource development, particularly as the company shifts focus toward clean and sustainable energy solutions. The licences may pave the way for future projects that bolster energy security and align with Australia’s transition to low-carbon alternatives.

Despite this strategic progress, Thor Energy faces serious financial headwinds. The company currently reports no revenue and is experiencing liquidity constraints. Bearish technical signals and negative valuation ratios also cloud its short-term outlook. Nevertheless, recent developments in clean energy initiatives offer a potential foundation for longer-term growth if successfully leveraged.

About Thor Energy

Thor Energy Plc is a resource exploration company focused on hydrogen, helium, and other key components of the clean energy transition. The company’s portfolio includes uranium and a range of energy-critical metals, with exploration efforts primarily concentrated in Australia and the United States.

Greatland Resources Limited (LSE:GGP) has initiated a bookbuild process for its planned Australian capital raise, seeking to secure up to AUD 50 million. The offering will involve the issuance of new ordinary shares on a non-pre-emptive basis, alongside the sale of shares held by Newmont NOL Pty Limited. This fundraising move supports Greatland’s strategy to dual-list on the Australian Securities Exchange (ASX), broadening its shareholder base and increasing visibility among investors in the Asia-Pacific region.

The offering targets institutional investors across Australia, New Zealand, and other qualified jurisdictions, while also including Australian retail investors. In parallel, the company has launched a UK Retail Offer aiming to raise up to €8 million, allowing retail shareholders in the UK to participate in the capital raise by subscribing to new shares.

Although Greatland Gold is currently navigating financial challenges, including a stretched valuation and ongoing concerns about its fiscal strength, recent technical indicators suggest positive market momentum. Strategic developments, such as the ASX cross-listing and associated fundraising, may position the company for future growth—especially as it moves from exploration toward production, a key step in improving its long-term financial outlook.

About Greatland Gold

Greatland Gold is a resource-focused mining company listed on London’s AIM market. Its operations are centered in Western Australia, where it explores and develops gold and copper assets. The company’s flagship projects include the Havieron gold-copper development and the adjacent Telfer mine, both situated in the resource-rich Paterson Province of the East Pilbara.

Glencore (LSE:GLEN) has confirmed that all regulatory approvals for the merger between its agricultural subsidiary Viterra and Bunge have been secured. The deal is now on track to close in early July. This merger represents a strategic move for Glencore, potentially boosting its global influence in the natural resources and agricultural supply chain sectors while broadening its operational footprint.

The transaction is expected to strengthen Glencore’s capabilities and service offerings, enhancing its competitive edge and creating opportunities for long-term value creation for stakeholders.

From a market perspective, Glencore is benefiting from positive technical indicators and strong commentary in recent earnings calls, pointing to solid operational performance and promising strategic initiatives. However, concerns remain around its mixed financial results and valuation pressures, particularly those linked to periods of negative earnings, which continue to weigh on investor sentiment.

About Glencore

Glencore is a global leader in the production, sourcing, marketing, and distribution of a wide array of commodities—over 60 in total. The company operates in more than 30 countries, supplying key materials to industries such as automotive, power generation, steelmaking, oil, and battery technology. Glencore also emphasizes sustainability, supporting global decarbonization goals while upholding high standards in human rights, corporate transparency, and security practices.

Triad Group Plc (LSE:TRD) has released its audited financial results for the year ended March 31, 2025, highlighting a period of strong growth and strategic progress. The company posted revenues of £21.4 million, reflecting a notable year-on-year increase. Gross profit margins also improved to 28.6%, while profit before tax reached £1.5 million.

In response to increased demand, Triad has expanded its consultancy team, enabling the business to secure high-profile contracts with several major UK government departments. The firm has also strengthened its digital services portfolio, reinforcing its position as a dedicated consultancy provider. These developments have supported ongoing dividend payments to shareholders and affirmed the company’s evolution into a focused digital consultancy.

Despite these achievements, Triad faces headwinds. There are concerns about declining revenue and profits in certain areas, and technical indicators point to bearish sentiment in the market. The company’s valuation appears stretched, driven by a high price-to-earnings ratio, though the dividend yield remains relatively solid. A recent positive development includes the vesting of Restricted Stock Units (RSUs), aligning executive incentives with long-term company performance—but this has not fully alleviated broader investor concerns.

About Triad Group Plc

Triad Group Plc is a UK-based consultancy firm specializing in digital services and transformation projects. With expertise spanning the public and private sectors—including government, law enforcement, and enterprise clients—Triad delivers independent, technology-agnostic solutions tailored to client needs.

SkinBioTherapeutics (LSE:SBTX) has taken a major step into mainstream retail by securing an exclusive partnership with UK high street giant Superdrug for its AxisBiotix™ line of products. This agreement marks a key commercial milestone as the company expands its footprint beyond direct-to-consumer channels.

To fuel this expansion and advance product development, the company has successfully raised £4.1 million through a combination of share placing and subscriptions. In addition, SkinBioTherapeutics is planning a retail offer aimed at giving existing shareholders a chance to participate in the fundraising.

The AxisBiotix-Ps supplement recently earned the National Psoriasis Foundation’s Seal of Recognition in the United States—an endorsement that is likely to boost its credibility and appeal within the American market.

Despite recent progress, SkinBioTherapeutics continues to face financial challenges, including net losses and cash flow limitations. Technical analysis reflects a bearish trend, and valuation remains pressured by negative earnings. Nevertheless, the recent business developments may signal a turning point, offering a more optimistic outlook for the future.

About SkinBioTherapeutics

SkinBioTherapeutics plc is a biotechnology company focused on improving skin health, particularly through solutions targeting inflammatory skin conditions. The firm’s flagship products, including the AxisBiotix™ range of food supplements, are part of its broader strategy to deliver innovative, science-backed skincare solutions to global markets.

U.S. stock futures for the Dow Jones, S&P 500, and Nasdaq are signaling a sharply lower start to trading on Friday, as escalating geopolitical tensions weigh on investor sentiment. The downturn comes after modest gains in Thursday’s session.

Concerns about a broader conflict in the Middle East intensified after Israel conducted airstrikes early Friday targeting Iranian nuclear and missile infrastructure. Reports indicate that at least three high-ranking Iranian military officials were killed in the strikes. In retaliation, Iran launched over 100 drones toward Israel, according to Israeli military sources.

The flare-up has sparked fears of a larger regional war, triggering a spike in oil prices as markets brace for potential supply disruptions.

Former President Donald Trump responded to the developments via a post on Truth Social, urging Iran to strike a nuclear agreement before violence escalates further. “There has already been great death and destruction,” Trump wrote, warning of even more severe attacks to come. “Iran must make a deal before there is nothing left… No more death, no more destruction.”

Despite the looming tensions, Wall Street managed a recovery Thursday following an early dip. The Dow Jones gained 101.85 points (+0.2%) to close at 42,967.62, while the S&P 500 rose 23.02 points (+0.4%) to 6,045.26. The Nasdaq also climbed 46.61 points (+0.2%) to finish at 19,662.48, with both the Dow and S&P hitting three-month closing highs.

The rebound was supported by fresh inflation data that showed producer prices rose just 0.1% in May, below economists’ expectations of 0.3%, according to the Labor Department. April’s figure was revised to a 0.2% decline.

On an annual basis, the producer price index increased 2.6%, in line with projections and slightly above April’s 2.5% pace.

“For the second straight day, inflation numbers came in softer than expected,” said Chris Zaccarelli, CIO of Northlight Asset Management. “This gives the Fed more flexibility to maintain its current stance without rushing into further tightening.”

Investors remained cautious, however, amid ongoing uncertainty over U.S. trade policy. Details on the U.S.-China trade framework announced Wednesday remain sparse. President Trump told reporters that within two weeks, he plans to send letters to various trade partners outlining new tariff rates. He also suggested he may extend the current 90-day tariff freeze, set to expire early next month, though he doesn’t believe it will be necessary.

Elsewhere in the market, gold stocks surged as precious metal prices jumped, lifting the NYSE Arca Gold Bugs Index by 1.5%. Utility stocks, typically sensitive to interest rates, also advanced, with the Dow Jones Utility Average rising 1.4%.

Tech, pharma, and networking stocks showed strength, but airline stocks continued to slide, extending losses from the prior session.

European shares on the DAX, CAC and FTSE100 have moved lower on Friday as heightened Middle East tensions offset encouraging inflation data from Germany and France.

Israel launched strikes against Iran, targeting nuclear facilities and ballistic missile factories as part of efforts “to damage Iran’s nuclear infrastructure, its ballistic missile factories and military capabilities.”

The overnight strikes on the country killed at least three of its senior military leaders. Iran retaliated by launching more than 100 drones toward Israeli territory.

In economic news, German consumer prices logged steady annual growth in May due to the continued decrease in energy prices, final data from Destatis showed today.

The consumer price index climbed 2.1 percent from a year ago, the same rate of growth as posted in April. The rate matched the flash estimate released on May 30.

Inflation based on the harmonized index of consumer prices softened to 2.1 percent from 2.2 percent in the previous month.

Elsewhere, French consumer price inflation moderated slightly as initially estimated in May to the lowest level in more than four years amid a slowdown in costs for services and a continued fall in energy prices, the latest data from the statistical office INSEE showed.

The consumer price index rose 0.7 percent on a yearly basis in May, slower than the 0.8 percent increase seen in April. That was in line with the flash data published on May 27. This was the lowest inflation rate since February 2021, when prices had risen 0.6 percent.

The German DAX Index is down by 1.1 percent, the French CAC 40 Index is down by 0.8 percent and the U.K.’s FTSE 100 Index is down by 0.1 percent.

Travel-related stocks slumped, with Lufthansa (TG:LHA), easyJet (LSE:EZJ), Wizz Air Holdings (LSE:WIZZ) and British Airways owner ICAG (LSE:IAG) falling 3-5 percent.

Oil & gas giant BP Plc (NYSE:BP) rallied 3 percent and Shell (LSE:SHEL) added 1.7 percent as crude prices jumped more than 4 dollars a barrel on supply concerns.

Technology group Ocado (LSE:OCDO) tumbled 3 percent after announcing that it has drawn down on a Letter of Credit under its deal with Kroger Co. (NYSE:KR), for $152 million, issued by the Bank of Nova Scotia.

Oxford Instruments (LSE:OXIG) lost 4 percent despite reporting strong results for the fiscal year ended March.

AstraZeneca PLC (LSE:AZN) has entered into a collaboration agreement with CSPC Pharmaceutical Group to advance the discovery of novel oral drug candidates, according to an announcement on Friday.

Under the terms of the agreement, CSPC will receive $110 million as an upfront payment. The deal also includes potential milestone payments of up to $5.22 billion.

The partnership aims to strengthen AstraZeneca’s drug development pipeline by leveraging CSPC’s capabilities in discovering new oral therapeutic candidates.

This collaboration represents a significant financial commitment from AstraZeneca, with the total potential value of the deal reaching $5.33 billion if all milestones are achieved.

Both pharmaceutical companies will work together to identify and develop new oral medications, though specific therapeutic areas targeted by the collaboration were not disclosed in the announcement.